ARTICLE | Clinical News
biOasis preclinical data
September 10, 2012 7:00 AM UTC
In a mouse xenograft model of aggressive human breast carcinoma, twice-weekly subcutaneous BT2111 completely halted tumor growth vs. a 400% increase in tumor size for placebo (p=0.0058). BT2111 was al...